Michele Malagola1, Raffaella Greco2, Stella Santarone3, Annalisa Natale3, Anna Paola Iori4, Luisa Quatrocchi4, Walter Barbieri4, Antonella Bruzzese4, Salvatore Leotta5, Alessandra Carotti6, Antonio Pierini6, Simona Bernardi1, Enrico Morello1, Nicola Polverelli1, Alessandro Turra1, Federica Cattina1, Lisa Gandolfi1, Benedetta Rambaldi1, Francesca Lorentino2, Francesca Serio2, Giuseppe Milone5, Andrea Velardi6, Robin Foà4, Fabio Ciceri2, Domenico Russo1 and Jacopo Peccatori2.
1 Chair of
Hematology, Dept of Clinical and Experimental Sciences, University of
Brescia, Bone Marrow Transplant Unit, ASST-Spedali Civili of Brescia.
2 IRCCS San Raffaele Scientific Institute, Milano, Italy, Hematology and Bone Marrow Transplantation Unit.
3 Santo Spirito Hospital, Pescara, Department of Hematology, Bone Marrow Transplant Center, Pescara.
4 Haematology, Department of Translational and Precision Medicine, Policlinico Umberto I, “Sapienza” University, Rome.
5 Department of Medical and Surgical specialties, Hematology Section , University of Catania, Catania.
6 Hematopoietic Stem Cell Transplantation Program, Hematology and Clinical Immunology Section, Department of Medicine, University of Perugia.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
represents one of the most severe life-threatening complications of
allogeneic stem cell transplantation (allo-SCT). Pre-emptive treatment
is highly effective, but toxicity and repetitive reactivation of CMV
represent a significant challenge in the clinical practice. The use of
anti-CMV specific immunoglobulins (Megalotect) is controversial.
Materials and Methods
|Table 1a. Population characteristics for prophylaxis treatment.|
|Table 1b. Population characteristics for pre-emptive treatment.|
|Table 2a. Details on CMV management and reactivation for recipient of prophylactic Megalotect infusion (n=14).|
|Table 2b. Details on CMV management and reactivation for recipient of pre-emptive Megalotect infusion (n=78).|
|Table 3. Overall transplantation outcomes % (95% CI).|